Physician profile
Albert L Riddle
NPI 1699724880
$524,203.72
in general payments reported to CMS, 2019-2025
12 companies · $87K in 2025
The $87K reported for 2025 was more than what 99% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $31K · 2021: $44K · 2022: $99K · 2023: $102K · 2024: $68K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Consulting Fee: $50K · Travel and Lodging: $45K · Food and Beverage: $11K · Education: $8.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,382.13 |
| Consulting Fee | $49,969.25 |
| Travel and Lodging | $44,914.26 |
| Food and Beverage | $11,090.30 |
| Education | $8.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $328,405.41 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $158,809.41 | 2022-2025 | Ingrezza |
| Sun Pharmaceutical Industries INC. | $20,759.59 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $6,200.83 | 2019 | |
| Qiagen, LLC | $3,906.91 | 2021 | |
| Cmp Pharma, INC. | $3,100.00 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $2,880.57 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $59.88 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $25.02 | 2021-2022 | |
| Biocompatibles, INC. | $21.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.02 | 2020 | |
| Neurelis, INC. | $16.21 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.